Amarin Corporation plc (NASDAQ:AMRN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
Amarin Corporation plc (the Company) held its annual shareholders
meeting (the Annual Meeting) on May15, 2017. There were
approximately 270,695,420 ordinary shares entitled to vote at the
Annual Meeting based on the April20, 2017 record date, of which
approximately 269,527,137 were held in the name of Citibank,
N.A., which issues Company-sponsored American Depositary Receipts
(ADRs) evidencing American Depositary Shares (ADSs) which, in
turn, each represent one ordinary share. Of the ordinary shares
entitled to vote, 127,375,277 shares, or approximately 46.78%,
were present and voting in person or by proxy at the Annual
Meeting. In accordance with the Companys Articles of Association,
the presence, in person or by proxy, of at least two shareholders
who held shares as of April20, 2017 would constitute a quorum for
the transaction of business at the Annual Meeting.
The matters set forth below were voted on at the Annual Meeting.
Detailed descriptions of these matters and voting procedures
applicable to these matters at the Annual Meeting are contained
in the Companys definitive proxy statement on Schedule 14A filed
with the Securities and Exchange Commission on April21, 2017. All
matters were approved by a show of hands in accordance with the
Companys Articles of Association. Set forth below are the total
number of shares voted for and against each matter, as well as
the total number of abstentions, discretionary votes and broker
non-votes with respect to each matter. Abstentions and broker
non-votes had no effect on the vote outcome.
| (1) | Ordinary resolution to re-elect Dr.Lars Ekman as a director: |
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
|
109,658,738 |
4,757,767 | 1,315,185 | 11,643,587 |
| (2) | Ordinary resolution to re-elect Mr.David Stack as a director: |
|
Votes For |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|||
|
98,957,175 |
15,459,207 | 1,315,308 | 11,646,587 |
The terms of the following directors continued after the meeting:
Mr.JohnF. Thero, Mr.Jan van Heek, Mr.PatrickJ. OSullivan,
Ms.Kristine Peterson and Mr.JosephS. Zakrzewski.
| (3) |
A non-binding advisory vote to approve the compensation of the Companys named executive officers: |
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
|
95,345,932 |
18,962,393 | 1,423,365 | 11,643,587 |
| (4) |
A non-binding advisory vote on the frequency of future advisory votes to approve the compensation of the Companys named executive officers: |
|
One Year |
Two Years |
Three Years |
Abstentions |
Broker Non-Votes |
||||
|
111,238,186 |
604,147 | 1,626,114 | 13,906,830 | 1,626,114 |
| (5) |
An ordinary resolution to appoint Ernst Young LLP as the Companys U.S. independent registered public accounting firm for 2016 and U.K. statutory auditors under Companies Act 2006 (to hold office until the conclusion of the next annual general meeting at which accounts are laid before the Company), and to authorize the Audit Committee to fix and determine the auditors remuneration:: |
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
|
125,453,905 |
674,653 | 1,246,719 |
| (6) |
An ordinary resolution to adopt and approve the proposed amendment to the Companys 2011 Stock Incentive Plan: |
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
|
85,977,421 |
28,224,537 | 1,529,732 | 11,643,587 |
| (7) |
An ordinary resolution to adopt and approve the proposed Amarin Corporation plc 2017 Employee Stock Purchase Plan: |
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
|
121,522,339 |
4,847,130 | 1,005,808 |
In light of the results of the non-binding advisory vote on the
frequency of future advisory votes to approve the compensation of
the Companys named executive officers, the Companys Board of
Directors has fixed the frequency of such vote at every one year.
***
About Amarin Corporation plc (NASDAQ:AMRN)
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Amarin Corporation plc (NASDAQ:AMRN) Recent Trading Information
Amarin Corporation plc (NASDAQ:AMRN) closed its last trading session 00.00 at 3.00 with 1,526,411 shares trading hands.
